Bausch Health Cos. said Thursday it plans to spin off its faster-growing eye-care business from its core pharmaceutical operations, breaking apart a company previous management had built through such acquisitions.
The eye-care unit, known as Bausch + Lomb, had $3.7 billion in revenue last year, compared with about $4.9 billion from the rest of the company.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:
Interested in talking to someone who was denied patient assistance by bauschhealth for a US $56k/year drug?
This should give some insight into its accounting fraud.
from Ye Olden Days $BHC $tsla $msft $googl $apo $lb currently down more than 86 percent from an August 2015 high of $262.52 and fell as low as $26.11 last week.